Email this article 
Hide
Show all
Original Research
In vitro antibacterial activity of tigecycline against multidrug-resistant bacteria isolated at the Sourô Sanou University teaching hospital in Bobo-Dioulasso, Burkina Faso
Submitted: 07 June 2025 | Published: 18 December 2025
About the author(s)
Odilon D. Kaboré, Laboratory of Bacteriology and Virology, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso; Burkina Faso National Reference Laboratory for Antimicrobial Resistance, Bobo-Dioulasso, Burkina Faso; Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Higher Institute of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina FasoMélissa J. Gonfouli, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso
Merci Muhigwa, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso
Abdourahmane Sow, Region Wide Laboratory Services, West African Health Organization, Bobo-Dioulasso, Burkina Faso
Fernand Michodigni, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso
André Nagalo, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso
Jacques Zoungrana, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; Higher Institute of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Department of Infectious and Tropical Diseases, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso
Arsène Hema, Department of Quality, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso
Augustin Konkobo, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Centre Muraz, Bobo-Dioulasso, Burkina Faso
Hervé Kafando, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso
Adama Ouattara, Higher Institute of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Division of Urology, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso
Armel Poda, Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; Higher Institute of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Department of Infectious and Tropical Diseases, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso
Sylvain Godreuil, Joint Research Unit, Research Institute for Development, National Center for Scientific Research, Inserm, Faculty of Infectious Diseases and Vectors: Ecology, Genetics, Evolution and Control, University of Montpellier, Montpellier, France
Abdoul-Salam Ouedraogo, Laboratory of Bacteriology and Virology, Sourô Sanou University Teaching Hospital, Bobo-Dioulasso, Burkina Faso; Burkina Faso National Reference Laboratory for Antimicrobial Resistance, Bobo-Dioulasso, Burkina Faso; Laboratory of Emerging and Re-emerging Pathogens, School of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; Higher Institute of Health Sciences, Nazi Boni University, Bobo-Dioulasso, Burkina Faso; and Centre Muraz, Bobo-Dioulasso, Burkina Faso
Abstract
Background: Tigecycline, an antibiotic effective against multidrug-resistant bacteria (MDRB), remains inaccessible in Burkina Faso’s hospitals for urgent care. Given the resulting therapeutic challenges and mortality in emergency services, evidence-based study of tigecycline’s efficacy on local bacterial clinical isolates is necessary before recommending its use.
Objective: This study aimed to evaluate the activity of tigecycline on MDRB isolates at the Sourô Sanou University Teaching Hospital laboratory, Burkina Faso.
Methods: This was a cross-sectional study with prospective and consecutive sampling of MDRBs. The latter included extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant strains (CRS), and methicillin-resistant Staphylococcus aureus (MRSA), which were isolated from urine, blood, pus and puncture fluids between 01 June 2022 and 31 August 2022. Antimicrobial susceptibility testing was conducted using the modified Kirby-Bauer method, and the results were interpreted according to the standard set by the European Committee on Antimicrobial Susceptibility Testing in 2021.
Results: A total of 117 MDRBs, including 93 Enterobacterales, 15 carbapenem-resistant Acinetobacter baumannii (CRAB), and 9 MRSAs were collected. The proportion of ESBL-E was 58% (68/117), followed by CRS (34%, 40/117) and MRSA (8%, 9/117). The activity of tigecycline was 95.5% (43/45) on ESBL-E, 72.5% (29/40) on CRS (including 10/15 CRAB), and 89% (8/9) on MRSA.
Conclusion: The activity of tigecycline was highly effective on ESBL-E, carbapenem resistant Enterobacterales and MRSA, and moderate on CRAB.
What this study adds: This was the first report on the evaluation of tigecycline activity on MDRBs in Burkina Faso. This non-marketed antibiotic in Burkina Faso could represent an alternative to spare carbapenems in the treatment of ESBL-E infections, and a last resort antibiotic against susceptible CRS infections in Burkina Faso’s hospitals.
Keywords
Sustainable Development Goal
Metrics
Total abstract views: 558Total article views: 559